- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04116164
Safety and Targeting of Anti-hk2 Antibody in mCRPC
A Phase 0 Study to Assess the Safety and Biodistribution of a Novel Radiolabeled Antibody Targeting Human Kallikrein-2 (hk2) in Subjects With Metastatic Castration-resistant Prostate Cancer.
This is an imaging trial, to develop h11B6 as a therapeutic radiopharmaceutical for men with mCRPC.
This imaging study will be conducted to confirm the safety and estimate the mass amount of antibody h11B6, and confirm in vivo tumor targeting of the antibody, using Indium-111 (111In) radiolabeled h11B6 in subjects with advanced prostate cancer. This study will also provide the dosimetric information crucial for Phase 1 therapy.
Study Overview
Status
Intervention / Treatment
Detailed Description
It is the intent to develop h11B6 as a therapeutic radiopharmaceutical for men with mCRPC. This Phase 0 study will be conducted to confirm the safety, estimate the mass amount, and confirm in vivo tumor targeting of the antibody. This study will use Indium-111 (111In) radiolabeled h11B6 in subjects with mCRPC to image known sites of disease and identify a favorable mass amount of antibody for satisfactory tumor targeting with minimal/no accumulation off-target. In cohort 1, In-111 labeled h11B6 will remain fixed at 2 mg, and additional h11B6 will be added in 2 sub-cohorts (8 mg and 18 mg respectively); up to 6 patients may be entered into a sub-cohort. Additional patients (up to 6) will be studied once the most favorable mass and imaging time point have been established, to establish targeting of antibody to known disease.
This study will provide the dosimetric information crucial for Phase 1 therapy.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Neeta Pandit-Taskar, MD
- Phone Number: 212-639-3046
- Email: pandit-n@mskcc.org
Study Contact Backup
- Name: Michael J Morris, MD
- Phone Number: 646-497-9068
- Email: morrism@mskcc.org
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects with mCRPC will be eligible if they meet the following criteria:
- Eastern Cooperative Oncology Group (ECOG) ≤ 1
- Histologically or cytologically confirmed adenocarcinoma of the prostate
- Castrate levels of testosterone (<50 ng/dL [1.74 nmol/L])
- Metastatic disease documented by imaging
- Documented progressive mCRPC with androgen involvement as defined by - Prostate Cancer Working Group 3
- Acceptable laboratory parameters
- At least 28 days since administration of any therapeutic radioactive isotope
- Able to tolerate the conditions required to perform imaging studies (e.g., lying flat for at least 1 hour).
Exclusion Criteria:
- Known hypersensitivity to proteins, or other allergic diathesis that, in the opinion of the investigator, makes an immune response to humanized antibody likely
- Radiotherapy or immunotherapy within 30 days, or single fraction of palliative radiotherapy within 14 days of administration of study agent
- Any condition that, in the opinion of the Investigator, would impair the subject's ability to comply with study procedures and required study visits
- Active, symptomatic, or untreated brain metastases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dosimetry and targeting
Three sub-cohorts in cohort 1 will receive one slow bolus IV injection of 2 mg 111In-DOTA-h11B6 with 0, 8 and 18 mg unlabeled h11B6 respectively. In cohort 2, up to 6 patients will receive a slow bolus IV injection of 2 mg 111In-DOTA_h11B6 with any unlabeled h11B6 as determined from cohort 1, and will be imaged at one time-point |
4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum pharmacokinetics
Time Frame: 6 months
|
Serum clearance kinetics of 111In-DOTA-h11B6, only in cohort 1, at each mass amount of antibody (2, 10, and 20 mg).
|
6 months
|
Radioactivity Biodistribution
Time Frame: 6 months
|
Radioactivity residence times in liver, kidneys and tumor, only in cohort 1, at each mass amount of antibody (2, 10, and 20 mg).
|
6 months
|
Radioactivity accumulation in known tumor sites
Time Frame: 9 months
|
Number of known metastatic lesions in which there is increased uptake of 111In, in both cohorts 1 and 2.
|
9 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael J Morris, MD, Memorial Hospital for Cancer and Allied Diseases
Publications and helpful links
General Publications
- Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ, Bostwick DG. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology. 1997 Jun;49(6):857-62. doi: 10.1016/s0090-4295(97)00108-8.
- Thorek DL, Watson PA, Lee SG, Ku AT, Bournazos S, Braun K, Kim K, Sjostrom K, Doran MG, Lamminmaki U, Santos E, Veach D, Turkekul M, Casey E, Lewis JS, Abou DS, van Voss MR, Scardino PT, Strand SE, Alpaugh ML, Scher HI, Lilja H, Larson SM, Ulmert D. Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Sci Transl Med. 2016 Nov 30;8(367):367ra167. doi: 10.1126/scitranslmed.aaf2335.
- Thorek DL, Evans MJ, Carlsson SV, Ulmert D, Lilja H. Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles. Thromb Haemost. 2013 Sep;110(3):484-92. doi: 10.1160/TH13-04-0275. Epub 2013 Aug 1.
- Vilhelmsson Timmermand O, Larsson E, Ulmert D, Tran TA, Strand S. Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2. EJNMMI Res. 2016 Dec;6(1):27. doi: 10.1186/s13550-016-0181-z. Epub 2016 Mar 17.
- McDevitt MR, Thorek DLJ, Hashimoto T, Gondo T, Veach DR, Sharma SK, Kalidindi TM, Abou DS, Watson PA, Beattie BJ, Timmermand OV, Strand SE, Lewis JS, Scardino PT, Scher HI, Lilja H, Larson SM, Ulmert D. Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun. 2018 Apr 24;9(1):1629. doi: 10.1038/s41467-018-04107-w.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Neoplastic Processes
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Neoplasm Metastasis
- Prostatic Neoplasms, Castration-Resistant
Other Study ID Numbers
- GID5490
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Disease
-
Memorial Sloan Kettering Cancer CenterCompletedMetastatic Solid Tumors of Metastatic DiseaseUnited States
-
Memorial Sloan Kettering Cancer CenterWithdrawnMetastatic Disease to Bone | Metastatic Disease to Soft TissueUnited States
-
M.D. Anderson Cancer CenterNot yet recruitingOligoProgressive Metastatic DiseaseUnited States
-
Institut CurieUnknownReccurent/Metastatic Solid Tumor DiseaseFrance
-
Washington University School of MedicineVarian Medical SystemsCompletedIntracranial Metastatic Disease From Any Solid MalignancyUnited States
-
University of California, San DiegoActive, not recruitingMetastatic CancerUnited States
-
The Cooper Health SystemCompletedCancer | Metastatic CancerUnited States
-
Duke UniversityRecruitingMetastatic Cancer | OligometastasisUnited States
-
Maastricht Radiation OncologyKarolinska Institutet; KU Leuven; Maastricht University Medical Center; Catholic... and other collaboratorsWithdrawnNSCLC Stage IV | Limited Metastatic DiseaseNetherlands
-
AmgenWithdrawnSolid Tumor | Metastatic Bone Disease
Clinical Trials on 111In-DOTA-h11B6
-
Radboud University Medical CenterCompleted
-
Janssen Research & Development, LLCRecruitingAdenocarcinoma | Prostatic NeoplasmsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
Paola Anna ErbaErasmus Medical Center; Jagiellonian University; Medical University Innsbruck; University... and other collaboratorsCompletedMedullary Thyroid CarcinomaAustria, Germany, Netherlands, Poland, Slovenia
-
IpsenWithdrawnColorectal Cancer | Pancreatic Ductal AdenocarcinomaBelgium, France
-
University Hospital, Basel, SwitzerlandUniversity Hospital Inselspital, Berne; Desirée and Niels Yde's Foundation,...CompletedEndogenous Hyperinsulinaemic HypoglycaemiaSwitzerland
-
CopharosUnknownBreast CancerUnited States
-
CopharosUnknownCarcinoma, Non-Small-Cell Lung | Lung Neoplasms | Brain Neoplasms | Metastases, NeoplasmUnited States
-
The First Affiliated Hospital of Xiamen UniversityRecruiting177Lu-DOTA-FAPI | 68Ga-DOTA-FAPI | TheranosticChina
-
Washington University School of MedicineNational Institutes of Health (NIH); National Institute for Biomedical Imaging...TerminatedHead and Neck CancerUnited States